文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

无标准心血管危险因素的急性冠状动脉综合征患者多种生物标志物的预后性能

Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors.

作者信息

Wang Le, Cong Hong-Liang, Zhang Jing-Xia, Li Xi-Ming, Hu Yue-Cheng, Wang Chen, Lang Jia-Chun, Zhou Bing-Yang, Li Ting-Ting, Liu Chun-Wei, Yang Hua, Ren Li-Bin, Qi Wei, Li Wen-Yu

机构信息

Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.

出版信息

Front Cardiovasc Med. 2022 Jul 27;9:916085. doi: 10.3389/fcvm.2022.916085. eCollection 2022.

DOI:10.3389/fcvm.2022.916085
PMID:35966532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9363620/
Abstract

BACKGROUND AND AIMS: Acute coronary syndrome (ACS) without standard modifiable cardiovascular risk factors (SMuRFs) represents a special case of ACS. Multiple biomarkers have been shown to improve risk stratification in patients with ACS. However, the utility of biomarkers for prognostic stratification in patients with ACS without SMuRFs remains uncertain. The aim of the present study was to evaluate the prognostic value of various biomarkers in patents with ACS without SMuRFs. METHODS: Data of consecutive patients with ACS without SMuRFs who underwent coronary angiography in Tianjin Chest Hospital between January 2014 and December 2017 were retrospectively collected. The primary outcome was the occurrence of major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, myocardial infarction and stroke. Seven candidate biomarkers analyses were analyzed using models adjusted for established risk factors. RESULTS: During a median 5-year follow-up, 81 of the 621 patients experienced a MACE. After adjustment for important covariates, elevated fibrinogen, D-dimer, N-terminal proB-type natriuretic peptide (NT-proBNP), and lipoprotein (a) [Lp(a)] were found to be individually associated with MACE. However, only D-dimer, NT-proBNP and Lp(a) significantly improved risk reclassification for MACE (all < 0.05). The multimarker analysis showed that there was a clear increase in the risk of MACE with an increasing number of elevated biomarkers and a higher multimarker score. The adjusted hazard ratio- for MACE (95% confidential intervals) for patients with 4 elevated biomarkers was 6.008 (1.9650-18.367) relative to those without any elevated biomarker-. Adding- the 4 biomarkers or the multimarker score to the basic model significantly improved the C-statistic value, the net reclassification index and the integrated discrimination index (all < 0.05). CONCLUSION: Fibrinogen, D-dimer, NT-proBNP and Lp(a) provided valuable prognostic information for MACE when applied to patients with ACS without SMuRFs. The multimarker strategy, which combined multiple biomarkers reflecting different pathophysiological process with traditional risk factors improved the cardiovascular risk stratification.

摘要

背景与目的：无标准可改变心血管危险因素（SMuRFs）的急性冠状动脉综合征（ACS）是ACS的一种特殊情况。多种生物标志物已被证明可改善ACS患者的风险分层。然而，生物标志物在无SMuRFs的ACS患者预后分层中的作用仍不确定。本研究的目的是评估各种生物标志物在无SMuRFs的ACS患者中的预后价值。 方法：回顾性收集2014年1月至2017年12月在天津胸科医院接受冠状动脉造影的无SMuRFs的连续ACS患者的数据。主要结局是主要不良心血管事件（MACE）的发生，定义为心血管死亡、心肌梗死和中风的复合事件。使用针对既定危险因素进行调整的模型分析了7种候选生物标志物。 结果：在中位5年的随访期间，621例患者中有81例发生了MACE。在对重要协变量进行调整后，发现纤维蛋白原、D-二聚体、N末端前B型利钠肽（NT-proBNP）和脂蛋白（a）[Lp（a）]升高分别与MACE相关。然而，只有D-二聚体、NT-proBNP和Lp（a）显著改善了MACE的风险重新分类（均P<0.05）。多标志物分析表明，随着升高的生物标志物数量增加和多标志物评分升高，MACE风险明显增加。与没有任何升高生物标志物的患者相比，有4种升高生物标志物的患者MACE的调整后风险比（95%置信区间）为6.008（1.9650-18.367）。将这4种生物标志物或多标志物评分添加到基本模型中显著提高了C统计值、净重新分类指数和综合判别指数（均P<0.05）。 结论：当应用于无SMuRFs的ACS患者时，纤维蛋白原、D-二聚体、NT-proBNP和Lp（a）为MACE提供了有价值的预后信息。将反映不同病理生理过程的多种生物标志物与传统危险因素相结合的多标志物策略改善了心血管风险分层。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc64/9363620/687126b31327/fcvm-09-916085-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc64/9363620/3156106a187e/fcvm-09-916085-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc64/9363620/1592209c63cd/fcvm-09-916085-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc64/9363620/687126b31327/fcvm-09-916085-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc64/9363620/3156106a187e/fcvm-09-916085-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc64/9363620/1592209c63cd/fcvm-09-916085-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc64/9363620/687126b31327/fcvm-09-916085-g0003.jpg

相似文献

[1]
Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors.

Front Cardiovasc Med. 2022-7-27

[2]
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.

Cochrane Database Syst Rev. 2021-12-21

[3]
Predictive Value of the Lipoprotein(a) to Prealbumin Ratio and of the NT-proBNP to LVEF Ratio for Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.

Heart Surg Forum. 2023-10-7

[4]
Optimization of GRACE Risk Stratification by N-Terminal Pro-B-type Natriuretic Peptide Combined With D-Dimer in Patients With Non-ST-Elevation Myocardial Infarction.

Am J Cardiol. 2021-2-1

[5]
Prognostic utility of a multi-biomarker panel in patients with suspected myocardial infarction.

Clin Res Cardiol. 2024-12

[6]
Prognostic Significance of Preprocedural N-Terminal Pro-B-Type Natriuretic Peptide Assessment in Diabetic Patients With Multivessel Coronary Disease Undergoing Revascularization.

Front Cardiovasc Med. 2021-10-6

[7]
Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

Clin Res Cardiol. 2007-9

[8]
A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.

J Intern Med. 2007-12

[9]
Effect of obstructive sleep apnea on prognosis in patients with acute coronary syndromes with varying numbers of standard modifiable risk factors: insight from the OSA-ACS study.

J Thromb Thrombolysis. 2023-7

[10]
B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study.

J Am Heart Assoc. 2014-7-22

引用本文的文献

[1]
The Association of Lipoprotein(a) with Major Adverse Cardiovascular Events after Acute Myocardial Infarction: A Meta-Analysis of Cohort Studies.

Rev Cardiovasc Med. 2025-5-15

[2]
Clinical characteristics and biomarkers feature analysis using a proteomics platform in young patients with acute coronary syndrome.

Front Cardiovasc Med. 2024-8-13

[3]
Prognostic significance of triglyceride-glucose index in acute coronary syndrome patients without standard modifiable cardiovascular risk factors.

Cardiovasc Diabetol. 2024-7-23

[4]
Association of clinical, laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors - rationale and design of the "Beyond-SMuRFs Study".

BMC Cardiovasc Disord. 2023-3-23

本文引用的文献

[1]
Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target.

Heart. 2022-12-13

[2]
Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins.

Am J Cardiol. 2022-4-1

[3]
D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis.

Thromb J. 2021-12-18

[4]
Coronary Artery Disease Without Standard Cardiovascular Risk Factors.

Am J Cardiol. 2022-2-1

[5]
Worse outcomes of ACS patients without versus with traditional cardiovascular risk factors.

J Cardiol. 2022-4

[6]
Progression of coronary atherosclerosis in patients without standard modifiable risk factors.

Am J Prev Cardiol. 2020-11-24

[7]
Prognostic Value of D-dimer in patients with acute coronary syndrome treated by percutaneous coronary intervention: a retrospective cohort study.

Thromb J. 2021-5-7

[8]
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.

Lancet. 2021-3-20

[9]
Oxidative Stress and Antioxidants in Atherosclerosis Development and Treatment.

Biology (Basel). 2020-3-21

[10]
Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease.

Cardiovasc Diabetol. 2020-3-19

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索